Abacavir + Lamivudine + NevirapineThird Party Manufacturing in India

This combination works by employing two different classes of antiretrovirals to inhibit the HIV-1 reverse transcriptase enzyme.

Abacavir and Lamivudine (NRTIs) act as false building blocks, incorporating into the viral DNA and causing chain termination. Nevirapine (an NNRTI) binds non-competitively directly to the reverse transcriptase enzyme, blocking its ability to convert viral RNA into DNA.

Unlike regimens that target only one mechanism, this multi-targeted approach significantly impairs the virus's ability to replicate and mutate. It is highly effective for maintaining viral suppression in patients who are stable on their antiretroviral therapy.

Therapeutic Uses

The Abacavir, Lamivudine, and Nevirapine combination is prescribed for:

• HIV-1 Infection Management: Used as a maintenance therapy for virologically suppressed patients.
• Antiretroviral Therapy (ART): Provides a complete regimen in a simplified dosing schedule.
• Prevention of Disease Progression: Maintains low viral loads and preserves immune function.

Why Manufacturers Choose This Combination

Simplifying treatment regimens is a major focus in HIV management, making triple-drug fixed-dose combinations highly valuable. Nevirapine-based regimens remain important alternatives in specific patient populations, especially in resource-limited settings.

This makes the Abacavir, Lamivudine, and Nevirapine combination a highly sought-after product for third party manufacturing in India, with consistent demand from export markets, government health programs, and institutional supply chains.